PURPOSE: To determine whether breast cancer subtype is associated with patterns of ipsilateral breast tumor recurrence (IBTR), either true recurrence (TR) or elsewhere local recurrence (ELR), among women with pT1-T2 invasive breast cancer (IBC) who receive breast-conserving therapy (BCT). METHODS AND MATERIALS: From Jan 1998 to Dec 2003, 1,223 women with pT1-T2N0-3 IBC were treated with BCT (lumpectomy plus whole-breast radiation). Ninety percent of patients received adjuvant systemic therapy, but none received trastuzumab. Biologic cancer subtypes were approximated by determining estrogen receptor-positive (ER+), progesterone receptor-positive (PR+), and human epidermal growth factor receptor-2-positive (HER-2+) expression, classified as luminal A (ER+ or PR+ and HER-2 negative [HER-2-]), luminal B (ER+ or PR+ and HER-2+), HER-2 (ER- and PR- and HER-2+), and basal (ER- and PR- and HER-2- ) subtypes. Imaging, pathology, and operative reports were reviewed by two physicians independently, including an attending breast radiologist. Readers were blinded to subtype and outcome. TR was defined as IBTR within the same quadrant and within 3 cm of the primary tumor. All others were defined as ELR. RESULTS: At a median follow-up of 70 months, 24 patients developed IBTR (5-year cumulative incidence of 1.6%), including 15 TR and 9 ELR patients. At 5 years, basal (4.4%) and HER-2 (9%) subtypes had a significantly higher incidence of TR than luminal B (1.2%) and luminal A (0.2%) subtypes (p < 0.0001). On multivariate analysis, basal subtype (hazard ratio [HR], 4.8, p = 0.01), younger age at diagnosis (HR, 0.97; p = 0.05), and increasing tumor size (HR, 2.1; p = 0.04) were independent predictors of TR. Only younger age (HR, 0.95; p = 0.01) significantly predicted for ELR. CONCLUSIONS: Basal and HER-2 subtypes are significantly associated with higher rates of TR among women with pT1-T2 IBC after BCT. Younger age predicts for both TR and ELR. Strategies to reduce TR in basal breast cancers, such as increased boost doses, concomitant radiation and chemotherapy, or targeted therapy agents, should be explored.
PURPOSE: To determine whether breast cancer subtype is associated with patterns of ipsilateral breast tumor recurrence (IBTR), either true recurrence (TR) or elsewhere local recurrence (ELR), among women with pT1-T2 invasive breast cancer (IBC) who receive breast-conserving therapy (BCT). METHODS AND MATERIALS: From Jan 1998 to Dec 2003, 1,223 women with pT1-T2N0-3 IBC were treated with BCT (lumpectomy plus whole-breast radiation). Ninety percent of patients received adjuvant systemic therapy, but none received trastuzumab. Biologic cancer subtypes were approximated by determining estrogen receptor-positive (ER+), progesterone receptor-positive (PR+), and humanepidermal growth factor receptor-2-positive (HER-2+) expression, classified as luminal A (ER+ or PR+ and HER-2 negative [HER-2-]), luminal B (ER+ or PR+ and HER-2+), HER-2 (ER- and PR- and HER-2+), and basal (ER- and PR- and HER-2- ) subtypes. Imaging, pathology, and operative reports were reviewed by two physicians independently, including an attending breast radiologist. Readers were blinded to subtype and outcome. TR was defined as IBTR within the same quadrant and within 3 cm of the primary tumor. All others were defined as ELR. RESULTS: At a median follow-up of 70 months, 24 patients developed IBTR (5-year cumulative incidence of 1.6%), including 15 TR and 9 ELR patients. At 5 years, basal (4.4%) and HER-2 (9%) subtypes had a significantly higher incidence of TR than luminal B (1.2%) and luminal A (0.2%) subtypes (p < 0.0001). On multivariate analysis, basal subtype (hazard ratio [HR], 4.8, p = 0.01), younger age at diagnosis (HR, 0.97; p = 0.05), and increasing tumor size (HR, 2.1; p = 0.04) were independent predictors of TR. Only younger age (HR, 0.95; p = 0.01) significantly predicted for ELR. CONCLUSIONS: Basal and HER-2 subtypes are significantly associated with higher rates of TR among women with pT1-T2 IBC after BCT. Younger age predicts for both TR and ELR. Strategies to reduce TR in basal breast cancers, such as increased boost doses, concomitant radiation and chemotherapy, or targeted therapy agents, should be explored.
Authors: Lisa A Carey; Charles M Perou; Chad A Livasy; Lynn G Dressler; David Cowan; Kathleen Conway; Gamze Karaca; Melissa A Troester; Chiu Kit Tse; Sharon Edmiston; Sandra L Deming; Joseph Geradts; Maggie C U Cheang; Torsten O Nielsen; Patricia G Moorman; H Shelton Earp; Robert C Millikan Journal: JAMA Date: 2006-06-07 Impact factor: 56.272
Authors: Gary M Freedman; Penny R Anderson; Alexandra L Hanlon; Debra F Eisenberg; Nicos Nicolaou Journal: Int J Radiat Oncol Biol Phys Date: 2005-04-01 Impact factor: 7.038
Authors: M Robson; T Gilewski; B Haas; D Levin; P Borgen; P Rajan; Y Hirschaut; P Pressman; P P Rosen; M L Lesser; L Norton; K Offit Journal: J Clin Oncol Date: 1998-05 Impact factor: 44.544
Authors: Martine J Piccart-Gebhart; Marion Procter; Brian Leyland-Jones; Aron Goldhirsch; Michael Untch; Ian Smith; Luca Gianni; Jose Baselga; Richard Bell; Christian Jackisch; David Cameron; Mitch Dowsett; Carlos H Barrios; Günther Steger; Chiun-Shen Huang; Michael Andersson; Moshe Inbar; Mikhail Lichinitser; István Láng; Ulrike Nitz; Hiroji Iwata; Christoph Thomssen; Caroline Lohrisch; Thomas M Suter; Josef Rüschoff; Tamás Suto; Victoria Greatorex; Carol Ward; Carolyn Straehle; Eleanor McFadden; M Stella Dolci; Richard D Gelber Journal: N Engl J Med Date: 2005-10-20 Impact factor: 91.245
Authors: Edward H Romond; Edith A Perez; John Bryant; Vera J Suman; Charles E Geyer; Nancy E Davidson; Elizabeth Tan-Chiu; Silvana Martino; Soonmyung Paik; Peter A Kaufman; Sandra M Swain; Thomas M Pisansky; Louis Fehrenbacher; Leila A Kutteh; Victor G Vogel; Daniel W Visscher; Greg Yothers; Robert B Jenkins; Ann M Brown; Shaker R Dakhil; Eleftherios P Mamounas; Wilma L Lingle; Pamela M Klein; James N Ingle; Norman Wolmark Journal: N Engl J Med Date: 2005-10-20 Impact factor: 91.245
Authors: Harry Bartelink; Jean-Claude Horiot; Philip M Poortmans; Henk Struikmans; Walter Van den Bogaert; Alain Fourquet; Jos J Jager; Willem J Hoogenraad; S Bing Oei; Carla C Wárlám-Rodenhuis; Marianne Pierart; Laurence Collette Journal: J Clin Oncol Date: 2007-06-18 Impact factor: 44.544
Authors: Paul L Nguyen; Alphonse G Taghian; Matthew S Katz; Andrzej Niemierko; Rita F Abi Raad; Whitney L Boon; Jennifer R Bellon; Julia S Wong; Barbara L Smith; Jay R Harris Journal: J Clin Oncol Date: 2008-04-14 Impact factor: 44.544
Authors: S Banerjee; J S Reis-Filho; S Ashley; D Steele; A Ashworth; S R Lakhani; I E Smith Journal: J Clin Pathol Date: 2006-03-23 Impact factor: 3.411
Authors: Anita Mamtani; Sujata Patil; Kimberly J Van Zee; Hiram S Cody; Melissa Pilewskie; Andrea V Barrio; Alexandra S Heerdt; Monica Morrow Journal: Ann Surg Oncol Date: 2016-05-11 Impact factor: 5.344
Authors: Bree R Eaton; Renjian Jiang; Mylin A Torres; Shannon T Kahn; Karen Godette; Timothy L Lash; Kevin C Ward Journal: Cancer Date: 2016-06-21 Impact factor: 6.860
Authors: Gary M Freedman; Barbara L Fowble; Tianyu Li; E Shelley Hwang; Naomi Schechter; Karthik Devarajan; Penny R Anderson; Elin R Sigurdson; Lori J Goldstein; Richard J Bleicher Journal: Breast J Date: 2014-05-26 Impact factor: 2.431
Authors: Itai M Pashtan; Abram Recht; Marek Ancukiewicz; Elena Brachtel; Rita F Abi-Raad; Helen A D'Alessandro; Antonin Levy; Jennifer Y Wo; Ariel E Hirsch; Lisa A Kachnic; Saveli Goldberg; Michelle Specht; Michelle Gadd; Barbara L Smith; Simon N Powell; Alphonse G Taghian Journal: Int J Radiat Oncol Biol Phys Date: 2012-05-30 Impact factor: 7.038
Authors: Magdalena A Cichon; Megan E Moruzzi; Tiziana A Shqau; Erin Miller; Christine Mehner; Stephen P Ethier; John A Copland; Evette S Radisky; Derek C Radisky Journal: Cancer Res Date: 2016-04-13 Impact factor: 12.701